# Sabra Health Care REIT Inc. (SBRA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Real Estate / Equity Real Estate Investment Trusts (REITs). Price $20.78, market value $5.3 billion.

## Valuation
- **P/E (trailing): 79.9×** (5-yr avg 85.8×, 3-yr avg 85.8×). Sabra Health Care REIT Inc. trades at 79.9× trailing earnings, close to its own five-year average of 85.8×. The Real Estate median in the September 2026 study was 25.2×. Forward P/E is 25.7×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 1.39**. A PEG of 1.39 is in the range usually read as fairly priced for its growth.
- **Price / sales: 11.9×**. Each dollar of revenue is priced at 11.9×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 1.3%**. The inverse of the P/E: 1.3% of the price is earned each year.

## Profitability
- **Net margin: 43.6%**. 43.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 5.5%**. 5.5% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on assets: 1.2%**. Each dollar of assets produces 1.2% of profit.

## Growth
- **Revenue growth (1 yr): 25.4%** (3-yr 24.1%/yr, 5-yr 18.0%/yr). Revenue grew 25.4% over the last year, against 18.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 18.5%** (5-yr -0.9%/yr). Earnings per share rose 18.5%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.90**. Debt is 0.90 times equity, moderate leverage.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 5.78%** ($1.20 per share, trailing). Sabra Health Care REIT Inc. yields 5.78%, an income-level yield.
- **Payout ratio: 186%**. The dividend exceeds earnings (186% payout), which is rarely sustainable outside REITs and one-off years.
- **Consecutive years of increases: 4**. 4 straight years of increases.
- **Dividend growth (5 yr): -2.3%/yr** (1-yr 0.0%). The dividend has not grown over five years.

## Analyst view
- **Analyst consensus: buy** (14 analysts). 14 analysts cover Sabra Health Care REIT Inc.; the consensus is buy, with an average price target of $22.79 (+10% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 14.0%** (YTD 13.0%, 3-mo 12.6%). The shares are up 14.0% over twelve months including dividends.
- **From 52-week high: -8.7%** (21.0% above the low). Trading 9% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): -0.21** (volatility 24%). Beta of -0.21 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SBRA · Page: https://foliofundamentals.com/stocks/sbra

Not investment advice.